Minocin (Minocycline HCl) Patent Expiration, LOE Window & CMS Spending

Minocin (Minocycline HCl) by Rempex A Wholly Owned Sub Of Melinta Therapeutics: FDA Orange Book LOE 2032-10-16, 16 AB generics, $767K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRempex A Wholly Owned Sub Of Melinta Therapeutics
FDA Application & PathwayN050444 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-10-16
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$767K
2024 Medicare Part D Spend$767K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 23.5% 2-yr change)